Long-term data shows promise in breast cancer biosimilar
The a three-year follow-up study comparing Ontruzant to Herceptin has found the biosimilar to be just as successful.
Read More
Tag: Ontruzant
UK launch for Europe’s first Herceptin biosimilar
MSD has launched in the UK Europe’s first biosimilar to Roche/Genentech’s Herceptin, providing an alternative option for treating early breast cancer, metastatic breast cancer and metastatic gastric cancer.
Read More
EU nod for first Herceptin biosimilar
European regulators have approved the first biosimilar of Roche’s blockbuster biologic Herceptin, issuing a green light for Samsung Bioepis’ Ontruzant.
Read More
CHMP backs 13 treatments for EU approval
Thirteen new therapies – including two biosimilars – have been backed for approval in Europe.
Read More
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
